Cat. No.: HY-B1829A

Dexamethasone phosphate disodium

(Synonyms: Dexamethasone 21-phosphate disodium)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 2392-39-4
Formula: C₂₂H₂₈FNa₂O₈P
Molecular Weight:516.40

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Dexamethasone phosphate disodium Chemical Structure

CAS No.: 2392-39-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Glucocorticoid receptor^[1]

All TGF-β Receptor Isoforms :

All Interleukin Related Isoforms :

In Vitro

Dexamethasone phosphate disodium (1, 2, 4 μM; 23 h) does not induce cytotoxicity in BV-2 microglial cells^[1].
Dexamethasone phosphate disodium (1, 2, 4 μM; 3 h pre-incubation, followed by 24 h LPS co-incubation) dampens LPS-induced secretion of RANTES, TGF-β1, and NO in BV-2 microglial cells, while dexamethasone phosphate disodium (4 μM; 24 h incubation alone) has no inhibitory effect on these mediators^[1].
Dexamethasone phosphate disodium (4 μM; 3 h pre-incubation, followed by 24 h LPS co-incubation) increases LPS-reduced production of IL-10 and MIP-1α in BV-2 microglial cells, while dexamethasone phosphate disodium (4 μM; 24 h incubation alone) reduces IL-10 production in untreated BV-2 microglial cells^[1].
Dexamethasone phosphate disodium (4 μM; 3 h pre-incubation in lower chambers, followed by 18 h LPS co-incubation) mitigates LPS-induced migration of BV-2 microglial cells, while having no effect on migration of untreated BV-2 microglial cells when used at 4 μM for 18 h incubation alone^[1].
Dexamethasone phosphate disodium (1, 2, 4 μM; 3 h pre-incubation, followed by 30 min LPS co-incubation) ameliorates LPS-induced degradation of IRAK-1 and IRAK-4, and inhibits LPS-induced activation of TRAF6, p-TAK1, and p-JNK in BV-2 microglial cells^[1].
Dexamethasone phosphate disodium (5×10^-6 M; 5-min intervals at 37°C) undergoes hydrolysis to Dexamethasone free alcohol in human whole blood in vitro with a first-order rate constant of 0.162 hr^-1, which is 25-fold slower than its in vivo conversion rate^[3].
Dexamethasone phosphate disodium (200 μM; 7 h) shows good stability with limited hydrolysis when incubated with human, porcine, or rat dermis for 7 hours, with 72.5-82.2% of the prodrug remaining intact^[4].
Dexamethasone phosphate disodium (50.8-51.8% drug loading; heated at 20 °C min^-1) intercalated into MgAl layered double hydroxides enhances the thermal stability of dexamethasone phosphate disodium, with its decomposition occurring at temperatures higher than those of free sexamethasone phosphate disodium^[5].
Dexamethasone phosphate disodium (50.8-51.8% drug loading) is successfully intercalated into MgAl layered double hydroxides via electrostatic interactions, with no denaturation of the drug molecules, as confirmed by preserved characteristic FT-IR bands and shifted phosphate group vibrations^[5].
Dexamethasone phosphate disodium (1.5 mg/mL; 50 hours) is efficiently encapsulated by the NPA₂ coacervate, which mediates sustained release of the drug over 50 hours in a cell-free in vitro system^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dexamethasone phosphate disodium (40 mM; transdermal (cathodal iontophoresis); 0.5 mA cm^-2; 5 hours) achieves significant plasma DEX levels, with a C_max of 1.62 μg mL^-1, and produces an in vivo flux of 1.66 μg cm^-2 min^-1 that matches the in vitro porcine skin flux in male Wistar rats^[4].
Dexamethasone phosphate disodium (0.25 mg/kg; i.p.; daily; 8 days) reduces asthma-related inflammation, cytokine production, and airway hyperresponsiveness in OVA-induced allergic asthma rats^[5].
Dexamethasone phosphate disodium (1.15 mg; p.o.; on days 1, 3, and 5) loaded in NPA₂ coacervate significantly reduces DSS-induced acute colitis severity (mean histopathology score 0.500), restores gut barrier function and microbiota diversity, and maintains low, sustained systemic drug exposure^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) (female)^[5]
Dosage:

0.25 mg/kg
Administration:

i.p.; daily; 8 days
Result:

Significantly reduced the number of eosinophils, macrophages, and neutrophils in bronchoalveolar lavage fluid compared to untreated OVA-challenged rats.
Suppressed OVA-induced elevations of IL-4 and IL-13 in bronchoalveolar lavage fluid.
Significantly inhibited airway hyperresponsiveness to methacholine, with reduced pulmonary resistance at methacholine doses of 100 and 330 μg/kg compared to untreated OVA-challenged rats.
Reduced peribronchial and perivascular inflammatory cell infiltration and airway wall thickening in lung tissue compared to untreated OVA-challenged rats.

Animal Model:

Sprague Dawley (SD) (female, 8-12 weeks, 200-300 g, dextran sulfate sodium-induced acute colitis)^[6]
Dosage:

1.15 mg
Administration:

p.o.; on days 1, 3, and 5
Result:

Reduced colon weight/length ratio to a mean value ~0.9 g/cm.
Lowered mean histopathology score to 0.500.
Significantly reduced colonic myeloperoxidase activity compared to untreated colitic rats.
Restored mRNA levels of tight junction-associated proteins ZO-1 and occludin-1.
Significantly reduced local mRNA levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF.
Increased local mRNA levels of anti-inflammatory cytokine IL-10.
Promoted M2 macrophage polarization.
Increased gut microbiota richness (observed OTUs), Chao diversity, and Shannon diversity, with bacterial composition clustering closely to healthy rats.

Chemical Information

CAS No. 2392-39-4
Appearance Solid
Molecular Weight 516.40
Formula C₂₂H₂₈FNa₂O₈P
Color White to off-white
SMILES

O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(COP(O[Na])(O[Na])=O)=O)=C1
Synonyms

Dexamethasone 21-phosphate disodium
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (12)

All Bio/Physico-chemical AssayRT-PCRHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Nat Commun

Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. [Abstract]

2021 Dec 9;12(1):7162. PMID: 34887414
Adv Sci (Weinh)

Emodin Alleviates Sepsis-Induced Multiorgan Damage by Inhibiting NETosis through Targeting Neutrophils BCL-10. [Abstract]

2025 Aug 8:e17129. PMID: 40779122

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]

DXMS (2 mg/kg; twice daily; ip). Kaplan-Meier survival curves over a 7-day period comparing the Sham, CLP septic group, Emodin treatment group, and DXMS treatment group.

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]

DXMS (2 mg/kg; twice daily; ip). Histopathological images showing tissue morphology and injury in the lung, liver, spleen, and kidney across the four experimental groups.
MedComm

Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. [Abstract]

2023 Jun 5;4(3):e293. PMID: 37287755

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: MedComm. 2023 Jun 5;4(3):e293. [Abstract]

Dexamethasone phosphate disodium (DXM, 5 mg/kg; i.p.; single dose) significantly alleviated tissue damage in acute lung injury (ALI).
Biomaterials

Polymer-based gene-drug co-delivery system effectively inhibits pathologic retinal neovascularization through dual anti-inflammatory and anti-neovascular actions. [Abstract]

2025 Sep 3:326:123680. PMID: 40916239
Biomaterials

Single-dose of integrated bilayer microneedles for enhanced hypertrophic scar therapy with rapid anti-inflammatory and sustained inhibition of myofibroblasts. [Abstract]

2025 Jan:312:122742. PMID: 39106821
Phytother Res

Chrysophanol Attenuates Glucocorticoid-Induced Osteoporosis by Targeting the E74-Like Factor 5/Osteoglycin-Regulated PI3K/AKT/mTOR Signaling Axis: An In Vitro and In Vivo Study. [Abstract]

2026 Apr;40(4):2143-2165. PMID: 41657040
Biochem Pharmacol

Glucocorticoid impairs angiogenesis-dependent osteogenesis by downregulating EphB4 in endothelial cells. [Abstract]

2025 Dec 2:244:117586. PMID: 41344513

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]

Masson-stained images of mice tibias. Masson staining indicated a marked decrease in new bone formation in DEX (Dexamethasone phosphate disodium, 1 mg/kg; i.p.; Once daily for 8 weeks)-treated mice.

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]

DEX (1 μM; 24 h). The mRNA expression levels of p53, p21 and p16 of bone ECs were detected via qRT-PCR.

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Dec 2:244:117586. [Abstract]

DEX (1 μM; 24 h). The protein expression of p53, p21, p16 and GAPDH was detected via Western blot and quantitative analysis.
Sci Rep

Ptbp1 knockdown induces conversion of rat spinal cord astrocytes into neuron like cells. [Abstract]

2025 Oct 14;15(1):35928. PMID: 41087401

Dexamethasone phosphate disodium purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Oct 14;15(1):35928. [Abstract]

Comparison of C3 mRNA levels between non-reactive astrocytes (Lucid), LPS-induced reactive astrocytes (LPS), and Dexamethasone phosphate disodium (DEX, 100 nM; 24 h)-reversed reactive astrocytes (LPS + DEX), with results normalized to the Lucid group (one-way ANOVA followed by Bonferroni post hoc test).
PLoS Pathog

Screening of different species reveals cat hepatocytes support HBV infection. [Abstract]

2025 Aug 4;21(8):e1013390. PMID: 40758741
Appl Biochem Biotechnol

Immunomodulatory Effects of Huaier Extract on Th1/Th2 Polarization Through IL-33/ST2 Axis Regulation in Allergic Rhinitis Pathogenesis. [Abstract]

2026 Apr 27. PMID: 42043703
J Neuroimmunol

Prior dexamethasone exposure attenuates the therapeutic efficacy of mouse bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis by fostering a hostile immunological microenvironment. [Abstract]

2026 Jan 15:410:578814. PMID: 41289704
NMR Biomed

Therapeutic Effects Assessment in Acute Lung Injury Using Hyperpolarized 129Xe Magnetic Resonance. [Abstract]

2026 Apr;39(4):e70254. PMID: 41790004

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (193.65 mM)

DMSO : 1 mg/mL (1.94 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9365 mL

9.6824 mL

19.3648 mL

5 mM

0.3873 mL

1.9365 mL

3.8730 mL

10 mM

0.1936 mL

0.9682 mL

1.9365 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (193.65 mM); Clear solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hui B, et al. Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(9):1761-1768. [Content Brief]

[2]. Bossa F, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013;19(9):1872-1879. [Content Brief]

[3]. Hare LE, et al. Bioavailability of dexamethasone. II. Dexamethasone phosphate. Clin Pharmacol Ther. 1975 Sep;18(3):330-7. [Content Brief]

[4]. Cázares-Delgadillo J, et al. Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability and transport kinetics. Eur J Pharm Biopharm. 2010;75(2):173-178. [Content Brief]

[5]. Wen-Rui Wang, et al. Dexamethasone sodium phosphate intercalated layered double hydroxides and their therapeutic efficacy in a murine asthma model. RSC Adv., 2015, 5, 23826-23834.

[6]. Zhao P, et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Nat Commun. 2021;12(1):7162. Published 2021 Dec 9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9365 mL	9.6824 mL	19.3648 mL	48.4121 mL
H₂O	5 mM	0.3873 mL	1.9365 mL	3.8730 mL	9.6824 mL
	10 mM	0.1936 mL	0.9682 mL	1.9365 mL	4.8412 mL
	15 mM	0.1291 mL	0.6455 mL	1.2910 mL	3.2275 mL
	20 mM	0.0968 mL	0.4841 mL	0.9682 mL	2.4206 mL
	25 mM	0.0775 mL	0.3873 mL	0.7746 mL	1.9365 mL
	30 mM	0.0645 mL	0.3227 mL	0.6455 mL	1.6137 mL
	40 mM	0.0484 mL	0.2421 mL	0.4841 mL	1.2103 mL
	50 mM	0.0387 mL	0.1936 mL	0.3873 mL	0.9682 mL
	60 mM	0.0323 mL	0.1614 mL	0.3227 mL	0.8069 mL
	80 mM	0.0242 mL	0.1210 mL	0.2421 mL	0.6052 mL
	100 mM	0.0194 mL	0.0968 mL	0.1936 mL	0.4841 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Dexamethasone phosphate disodium

12 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dexamethasone phosphate disodium

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

TGF-beta/Smad Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Reprogramming Compound Library

Lipid Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Animal Drug Library

FDA Kinase Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Dexamethasone phosphate disodium

All TGF-β Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (12)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dexamethasone phosphate disodium Related Classifications

HY-B1829A Related Classifications